The National Institute for Clinical Excellence, UK published guidelines in 2007 encouraging the use of low molecular weight heparin (LMWH) joint replacement surgery. Subsequently, our hospital adopted these guidelines in the treatment of total hip replacements. This study is based on our prospective database of total hip replacements between 2005 and 2009 and compares the complication and mortality rates pre- and post institution of the NICE guidelines.

We analysed prospectively collected data on 686 patients who underwent a primary total hip replacement done by a single surgeon between January 2005 and April 2009. We compared the incidence of mortality, pulmonary embolism, myocardial infarction and intracranial bleeding between the two groups. Prior to the guidelines, all patients were treated for the duration of their admission with 75mg aspirin followed by 4 weeks after discharge. Subsequent to the guidelines, the treatment changed to 40mg of LMWH (Clexane) while an inpatient with aspirin being prescribed for 4 weeks on discharge. Patients unable to tolerate aspirin were treated with low molecular weight heparin. High risk patients (previous pulmonary embolism, previous deep vein thrombosis, family history) were treated with 6 weeks of warfarin. Each patients was reviewed at 8 weeks and 6 months following surgery, and adverse incidents were documented at each review or incident.

Results: 686 patients were identified from the study – 328 pre and 358 post implementation of the NICE guidelines. In the pre-guideline group the mortality was 0.6%, with the incidence of pulmonary embolism being 0.3%, myocardial infarction 0.9% and intracranial bleed 0.3%. Both complications of myocardial infarction occurred early in the post-operative stage and were fatal. The post-guideline group had a mortality rate of 0.2%, with the incidence of pulmonary embolism being 0.2% and intracranial bleeding 0.2%. No myocardial infarctions were noted in this group. The single death was as a result of an intracranial bleed. The was no significant statistical difference in the incidence of mortality, pulmonary embolism, myocardial infarction or intracranial bleeding between the two groups (p value > 0.05, 95% confidence interval). There were no complications in the warfarinised patients of which there were equal numbers in both groups (16).

Conclusion: This study has shown that the change in thromboprophylaxis has not had a significant effect on complication rates in primary total hip replacements and that our mortality rate (0.4%) compares favourably with recent literature. The lack of complications in the war-farinised group probably reflects that high risk patients were identified in the screening process and commenced on warfarin early in the post operative period. Note must be made of the single death due to an intracranial bleed while on low molecular weight heparin.

We assessed polyethylene wear and osteolysis in 15 patients (30 hips) undergoing staged bilateral total hip arthroplasty, who had a cemented hip arthroplasty on one side and a hybrid arthroplasty on the other. All factors apart from mode of acetabular component fixation were matched. Wear was measured radiographically using Livermore’s technique.

The mean clinical and radiological follow-up was 11.2 years for the cemented arthroplasties and 10.7 years for the hybrid arthroplasties. Mean annual linear wear rate for the cemented cups was 0.09mm/year, and 0.14mm/year for the uncemented cups. This difference was statistically significant (p=0.03), confirming previous reports that polyethylene wear in uncemented cups is greater than in cemented cups. Polyethylene wear in the uncemented cup exceeded wear in the cemented cup by more than > 0.1mm/year in 5 patients, 4 of whom had a BMI of greater than 30.

No periacetabular osteolysis was noted. Femoral osteolysis was present in 5 hybrid arthroplasties and 2 cemented arthroplasties. Zone 7 femoral osteolysis occurred in 3 patients on the side of the hybrid arthroplasty, multifocal femoral osteolysis not involving zone 7 was seen in 2 patients in both hips.

Introduction: The correction of anaemia prior to total hip arthroplasty reduces surgical risk, hospital stay and cost. This study considers the benefits of implementing a protocol of identifying and treating pre-operative anaemia whilst the patient is on the waiting list for surgery.

Methods: From a prospective series of 301 patients undergoing elective total hip arthroplasty (THA), patients identified as anaemic (Hb< 12 g/dl) when initially placed upon the waiting list were appropriately investigated and treated. Pre- and post- operative haemoglobin (Hb), need for transfusion, and length of hospital stay were collated for the entire patient cohort.

Result: 7.6% of patients were anaemic when initially placed upon the waiting list for THA and had a higher transfusion rate (25% to 4%, p< 0.05) and longer hospital stay (7.5 to 6.6 days, p< 0.05). Over 40% of these patients responded to investigation and treatment whilst on the waiting list, showing a significant improvement in Hb level (10.1 to 12.7 g/dl) and improved transfusion rate.

Discussion: Quantifying the haemoglobin level of patients when initially placed on the waiting list helps highlight those at risk of requiring a post-operative blood transfusion. Further, the early identification of anaemia allows for the utilization of the waiting list time to investigate and treat these patients. For patients who respond to treatment there is a significant reduction in the need for blood transfusion with its inherent hazards.